Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, multi-center, expanded access study with fingolimod in patients with relapsing-remitting multiple sclerosis for whom no suitable therapy exists [Studio in aperto, multicentrico, di accesso allargato a fingolimod in pazienti con sclerosi multipla recidivante-remittente, per i quali non esiste una adeguata alternativa terapeutica]

Next Previous
X
Search
Trial Profile

An open-label, multi-center, expanded access study with fingolimod in patients with relapsing-remitting multiple sclerosis for whom no suitable therapy exists [Studio in aperto, multicentrico, di accesso allargato a fingolimod in pazienti con sclerosi multipla recidivante-remittente, per i quali non esiste una adeguata alternativa terapeutica]

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Expanded access

    • Most Recent Events

    • 22 Jun 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 11 Oct 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top